Sanofi Wants Jury Verdict Axed In Amgen Drug Patent Row

Law360, Los Angeles (May 24, 2016, 10:01 PM EDT) -- Sanofi urged a Delaware federal judge Monday to toss a jury's verdict finding rival Amgen's cholesterol drug patents valid and order a new trial or enter judgment against Amgen in its infringement row, saying the court erred in excluding evidence and throwing out Sanofi's obviousness defense.

The patents the jury upheld in March describe antibodies that block the receptor in human genes that can cause certain cholesterol levels to spike. They cover Amgen's Repatha, a cholesterol-reducing drug that competes with Sanofi and Regeneron's Praluent.

Sanofi SA and Regeneron Pharmaceuticals Inc. argued the court excluded evidence after January 2008 showing that the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!